Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001593968-20-002227
Filing Date
2020-11-20
Accepted
2020-11-20 15:56:39
Documents
1
Period of Report
2020-11-19

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT primary_01.html 4  
1 PRIMARY DOCUMENT primary_01.xml 4 4534
  Complete submission text file 0001593968-20-002227.txt   6009
Mailing Address NGM BIOPHARMACEUTICALS, INC. 333 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Business Address
RIEFLIN WILLIAM JL (Reporting) CIK: 0001182471 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-38997 | Film No.: 201332359

Mailing Address 561 ECCLES AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 561 ECCLES AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 489-9000
RAPT Therapeutics, Inc. (Issuer) CIK: 0001673772 (see all company filings)

EIN.: 473313701 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations